Rates of contralaterai prophylactic mastectomy (CPM) have increased dramatically, particuiariy among younger women with breast cancer, but iittle is i<nown about how women approach the decision to have CPM.
R
ates of contralaterai prophylactic mastectomy (CPM) have increased dramatically among women treated for early-stage breast cancer in recent years in the United States. In the late 1990s, between 4% and 6% of women who had mastectomies also underwent CPM, whereas in more recent years the reported range has increased to between 11% and 25%, a 3-to 4-fold change (1) (2) (3) (4) .
The trend for bilateral mastectomy at diagnosis of unilateral breast cancer is particularly notable among young women, with younger age consistendy identified as a predictor of CPM (1) (2) (3) (4) (5) . Although mastectomy is a safe procedure and major complications are rare, there are cosrnetic concerns as well as clinically significant potential long-term sequelae, including numbness of the chest skin and chronic pain, that may affect quality of life (QOL). With many women opting for reconstructive surgery, the potential for an extended recovery time, additional surgical complications, and decrease in strength or function due to muscles being moved or stretched must also be considered.
Most important, the value of the procedure for most women with unilateral early-stage breast cancer is unclear. Although CPM markedly reduces the risk for cancer in the unaffected breast, the risk for contralateral breast cancer (CBC) in most women (those without a clear cancerpredisposing mutation) is low: approximately 0.5% to 0.75% per year among women with early-stage disease (6, 7) . Moreover, this risk has decreased over time because of the widespread use of adjuvant therapy (8) . A recent study of women with a family history of breast cancer who did not harbor a known genetic predisposition reported that the 10-year cumulatiye risk for CBC was less than 15% in women younger than 40 years at diagnosis of the index cancer (9) . Among the youngest women in this study with a delei:erious BRCAl or BRCA2 mutation, the 10-year cumulative risks ranged from approximately 24% to 31% (9) . Findings are mixed about whether contralateral mastectomy results in improved survival among high-risk women who have already had breast cancer (10, 11), probably because not only is the absolute benefit from the procedure 
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Context
Increasing numbers of women with breast cancer have contralateral prophylactic mastectomy.
Contribution
This study involved 123 women aged 40 years or younger with cancer in 1 breast who had undergone bilateral mastectomy. Common reasons given for choosing prophylactic mastectomy were desires to avoid developing contralateral breast cancer (98%) and to improve survival (94%). Women often overestimated the risk for contralateral breast cancer, but only 18% believed that bilateral mastectomy improved survival.
Caution
Women were surveyed 2 years after surgery.
Implication
Although women may know that contralateral prophylactic mastectomy does not improve survival, many choose it with the hope of extending life.
-The Editors modest, but young women are, on average, at the greatest risk for systemic recurrence and death from their initial breast cancer (12) and thus have a heightened competing risk. Having CPM is not likely to affect risk for metastatic disease from a woman's primary breast cancer. Thus, when CPM is being considered for women with early-stage breast cancer, there is an inherent tension between the clinician's obligation to practice evidence-based medicine and "do no harm" by avoiding unnecessary procedures and a desire to respect patient preference.
Studies examining the decision to have CPM have been limited, especially among younger women with breast cancer. There are few available data related to the decisionmaking process, including how well-informed women were about CPM when they made the decision. In this study, we sought to describe perceptions, knowledge, and satisfaction with CPM among participants enrolled in a large prospective cohort study of women diagnosed with breast cancer at age 40 years or younger. A better understanding of how patients approach the decision to have CPM can potentially inform clinicians who are counseling young women with early-stage disease about their local therapy and preventive decisions.
METHODS

Design Overview
The YWS (Helping Ourselves, Helping Odiers: Young Women's Breast Cancer Study) is an ongoing prospective cohort study established to explore biological, medical, and QOL issues specific to young women diagnosed with breast cancer. After enrollment, women are mailed surveys twice a year for the first 3 years after diagnosis and annually for an additional 7 years. Beginning in November 2010, a 1-time supplementary questionnaire ("CPM survey") was mailed to .women who enrolled between November 2006 and November 2010 and reported bilateral mastectomy on any survey completed within the first year after diagnosis. This study was approved by the Institutional Review Board at the Dana-Farber/Harvard Cancer Center and other participating sites.
Study Participants
As of November 2010, study enrollment sites for the YWS included 4 academic and 5 community hospitals located in eastern Massachusetts and 1 academic site in Toronto, Ontario, Canada. The CPM substudy was open only to women enrolled from centers in Massachusetts. English-speaking women with a diagnosis of breast cancer at age 40 years or younger are eligible for the YWS. For the sites in Massachusetts, women are identified within 6 months of diagnosis by using the Rapid Case Identification Core of the Dana-Farber/Harvard Cancer Center and ate subsequently invited to enroll in the study.
Of the 550 women enrolled between November 2006 and November 2010, a total of 159 (29%) from 8 of 9 participating centers reported having a bilateral mastectomy between September 2006 and November 2010 (Figure) . The response rate was 83%, with 132 women completing the CPM survey. We excluded an additional 9 women from the analytic sample who had bilateral breast cancer diagnosed before (« = 3) or after surgery (n = 4) or bilateral prophylactic indications, defined as having bilateral mastectomy without knowledge of cancer in either breast before surgery, with cancer detected only afiier surgery (w = 2). A total of 123 women were included in this analysis.
Measurements
Sociodewographic and Disease Characteristics
Participants self-reported age, race, ethnicity, marital status, education, employment, and insurance status on the baseline survey, which was completed an average-of approximately 5 months after diagnosis. Cenetic mutation information {BRCAl or BRCA2, mutation of uncertain clinical significance, not tested or unknown, or no mutation) and family history of breast and ovarian cancer were also self-reported on the survey completed by participants 1 year after diagnosis. We categorized women who reported having a BRCAl or BRCA2 mutation or a mutation of uncertain clinical significance as "mutation carriers" and all others as "noncarriers." Medical record review was used to ascertain stage, grade, human epidermal growth factor receptor-2 status, and hormone receptor status, as well as to reconcile missing sociodemographic information and verify self-report of genetic testing results. We did not use medical record review to ascertain whether diagnostic procedures (for example, magnetic resonance imaging or ultra-sonography) were used before surgery to exclude the possibility of contralateral disease.
CPM Survey
The CPM survey (Supplement, available at www .annals.org) consisted of 23 items related to decision making, knowledge, risk perceptions, and breast cancer worry. This 1-time cross-sectional survey was developed specifically for this study and was based on the expert knowledge of 3 of this article's authors, who have extensive experience measuring decision making, risk perceptions, and knowledge outcomes in patients with breast cancer.
Decision Making
We presented women with a comprehensive list of potential reasons for having CPM, including cosmetic, preventive, genetic, and cancer-related (for example, fear of recurrence or history of abnormal mammogram or magnetic resonance imaging result), and asked them to indicate on a 5-point scale (extremely important, very important, somewhat important, not at all important, or not sure) the degree to which these factors played a role in their decision. We also used this scale to assess the influence of different sources of information (physicians, nurses, family and friends, and media) on the decision to have CPM.
The SURE (Sure of myself. Understanding information. Risk-benefit ratio. Encouragement) Scale comprises 4 items from the Decisional Conflict Scale (13) that measure patients' uncertainty about which treatment to choose and factors contributing to uncertainty (feeling uninformed, unclear values, or lack of support in decision making). The SURE Scale has been shown to have modest reliability and good construct validity in a sample of English-speaking patients and a sample of French-speaking patients facing treatment decisions (14) . Scores range from 0 to 4, with lower scores indicating higher decisional conflict.
We measured respondents' confidence about whether the choice to have CPM was right for them by using a scale of 0 (not confident) to 10 (extremely confident). A second question asked women whether they would choose CPM if making the decision again (yes, definitely; yes, probably; no, probably not; no, definitely not; or not sure). We also asked women to indicate whether their experience with several surgical and QOL outcomes, including pain, cosmesis, sense of sexuality, and recovery from reconstruction, was better than expected, worse than expected, or about what they expected.
One item asked about who first proposed having CPM (patient, oncologist, surgeon, family, or friend). Additional items aimed to assess the extent of discussion with a physician about the risk for contralateral cancer, reasons to have or not to have CPM, and personal feelings about CPM. We graded responses for these discussions as a lot, some, a little, or not at all.
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Knowledge, Risk Perception, and Breast Cancer Worry
We asked respondents to estimate the number of women with early-stage breast cancer, out of 100, who would develop cancer in the contralateral breast after either a single mastectomy or lumpectomy with radiation and the number who would develop recurrent breast cancer in the chest wall of the breast removed prophylactically. Other items pertaining to breast cancer knowledge were adapted from the Breast Cancer Surgery Decision Quality Instrument (15) and included an estimate of the number of women diagnosed with and treated for early-stage breast (6) 3 (2) 101 (82) 19 (15) 3 (2) 104 (85) 14 (11) 5 (4) 45 (37) 75 (61) 3 (2) 118 (96) 1 (1) 4 (3) 74 (60) 49 (40) 42 ( 8 (7) 41 (33) 56 (46) 17 (14) 1 (1) 116 (94) 7 (6) 32 (26) 87 (71) 4 (3) 76 (62) 38 (31) 9 (7) 74 (60) 22 (18) 8 (7) 4 (3) 15 ( cancer who will eventually die of the disease (most will die of the disease, about half will die of the disease, or most will die of something else) and an item about differences in breast cancer survival by treatment type (mastectomy, bilateral mastectomy, or lumpectomy with radiation). Items measuring risk perception included how much (a lot, some, a little, or not at all) respondents believed having the "other" breast removed would reduce the subsequent risk for CBC and whether the chance of their cancer returning was higher than, lower than, or about the same as that of other women with early-stage breast cancer. In addition, 1 item assessed how worried women currently were about breast cancer (a lot, some, a little, or not at all) and another assessed past concern (extremely, very, somewhat, a little, or not concerned at all) about being diagnosed with CBC in the future.
Statistical Analysis
Because the aim of this study was to better understand how women' approached the decision to have CPM, the analyses we conducted were primarily descriptive. Means, medians, and frequency distributions were calctilated for continuous and categorical outcomes. For the measures of risk perception and knowledge, we stratified results by mutation carrier status. For items with a response rate less than 100%, the number of respondents who answered the question is specified. To assess whether results would differ when high-risk women were excluded, we repeated the analyses and excluded women who were identified as mutation carriers (w = 34). All analyses were conducted using SAS, version 9.2 (SAS Institute, Cary, North Carolina).
Role of the Funding Source
The funding sources had no role in the design, conduct, or analysis of the study or the decision to submit the manuscript for publication.
RESULTS study Population Characteristics
Patient and disease characteristics for the study population are presented in Table 1 . Women completed the survey an average of 2.1 years (range, 0.1 to 4.3 years) after having CPM, and the median age at breast cancer diagnosis was 37 years (range, 26 to 40 years). Ninety-four percent of women had reconstructive surgery. Most women had stage I or stage II breast cancer, and 60% of tumors . were estrogen receptor-positive.
Approximately one quarter of women were carriers of a BRCAl or BRCA2 mutation. Twenty-six percent had a first-degree relative and 62% had a second-or third-degree relative who had been diagnosed with breast or ovarian cancer. Among mutation carriers, 41% had a first-degree relative with breast or ovarian cancer; among noncarriers, this proportion was 20% (Appendix Table 1 , available at www.annals.org). Most women (56%) with a mother or sister with breast or ovarian cancer were not mutation car- • -
CPM = contralateral prophylactic mastectomy. * Data are numbers (percentages). Participants were queried about additional items related to diagnostic work-up (e.g., magnetic resonance imaging or ultrasonography) and prior chest radiation, but these items were not included in the table.
riers (Appendix Table 2 , available at www.annals.org). A higher proportion of women who had CPM were mutation carriers or had a family history of breast or ovarian cancer compared with women who did not report bilateral mastectomy (Appendix Tables 3 and 4 , available at www .annals.org). Table 2 lists the responses to the items that assessed the importance of various factors that¡might have played a role in the decision to have CPM. Almost all women surveyed (98%) responded that the desire to decrease the risk for CBC was an extremely or a very important reason. A similarly high proportion of women ranked peace of mind (95%), desire to improve survival or extend life (94%), feeling at increased risk for CBC (87%), and desire to prevent breast cancer from spreading to other parts of the body (85%) as extremely or very important factors in their decision. Few women reported advice from family or friends or abnormal screening test results (for example, magnetic resonance imaging or mammogram before surgery) as important reasons for choosing CPM. Appendix Table 5 (available at www.annals.org) includes importance of family history as a reason to have CPM among women with and without a family history of breast or ovarian cancer.
Decision Making
Overall satisfaction with the decision was high: 80% of women were extremely confident in their decision to have CPM, and 90% of respondents would have definitely chosen CPM if deciding again. Among women who responded to the items about making the choice to have CPM (« = 120), almost all believed t:hat they knew the risks and benefits of each option (97%), were clear about which benefits and risks mattered most (96%), had enough support and advice to make the choice (92%), and were sure CPM was the right choice for them (93%). Overall, 87% of respondents scored 4 out of 4, indicating no decisional confiict as measured by the SURE Scale.
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Physicians were the most important sources of information for the decision, followed by family and friends. Of the women who responded (n = 120), more than half (n = 68) indicated that they were the first to bring up the idea of having their contralateral breast removed. Although 80% of women (97 of 121) reported that they spoke with their physicians to at least some extent about the reasons for having CPM, only 51% (62 of'122) reported that their physicians discussed the reasons not to have the surgery.
Many women reported that several outcomes associ-: ated with surgery were worse than they had expected (Table 3). Thirty-three percent reported that the number of surgeries or procedures needed was higher than expected, and 28% indicated that numbness or tingling in the chest was worse than they had expected. With respect to QOL outcomes, 42% reported that their sense of sexuality was worse than they expected after surgery, and nearly one third indicated that self-consciousness about their appearance was also worse than expected. Table 4 details risk knowledge and. perception by mutation carrier status. Regarding the risk for CBC without CPM, mutation carriers estimated that a median of 20 out of 100 women vvould develop cancer in their other breast in the 5 years after unilateral breast cancer treatment, and noncarriers estimated that a median of 10 out of 100 women would. Mutation carriers and noncarriers both estimated that a median of 5 out of 100 women would have chest wall recurrence in the area of the unaffected breast, despite having both breasts removed, in the 5 years after treatment.
Knowledge and Perception of Breast Cancer Risk
More than half of women (56%) without a genetic mutation believed that the chance of their cancer returning was about the same as in other women with early-stage breast cancer, whereas 19% believed that the chance was higher and 20% thought it was lower. In contrast, among mutation carriers, 21% believed this risk to be about the IVESEARCH Contralaterai Prophylactic Mastectomy Among Young Women With Breast Cane (25) 37 (30) 10 (8) 19 (15) 28 (23) 17 ( 29 (24) 32 (26) 1 (1) 14(11) 2 (2) 2(2) Recovery from reconstructive surgervt Complications or problems from reconstructive surgeryt Filling up expanderst 33 (27) 26 (21) 28 (23) 39 (32) 34 (28) 32 (26) 41 (33) 30 (24) 29 (24) 2 (2) 24 (20) 25 (20) 8 (7) 9(7) 9(7) same as in other women, 32% approximated this risk to be higher, and 41% estimated it to be lower. Among mutation carriers, 94% believed that removing the unaffected breast would decrease their risk for CBC by a lot; among noncarriers, 67% responded that removing the unaffected breast would reduce their risk for CBC by a lot.
A higher proportion of noncarriers (84%) than mutation carriers (74%) correctly answered that most women with early-stage breast cancer will die of something other than breast cancer. Although most carriers (71%) and noncarriers (73%) responded that survival does not differ among treatment options, a higher proportion of carriers (24%) than noncarriers (15%) responded that women who have bilateral mastectomy will live longer.
Breast Cancer Worry
Eighty-seven percent of women (110 of 126) reported that they had been extremely or very concerned about being diagnosed with CBC in the future. Among women who responded to the item about current breast cancer worry (« = 118), 90% were at least a little worried about their breast cancer at the time of the survey.
When all analyses were done excluding women who had a BRCA mutation or reported a mutation of uncertain clinical significance (« = 34), the results did not change substantially (Appendix Tables 6 to 12 , available at www .annals.org).
DISCUSSION
To our knowledge, our study is the largest to date that examines decision making, risk perceptions, and psychosocial aspects related to CPM among young women with breast cancer. Among those at increased risk for CBC due to a cancer-predisposing mutation and among noncarriers, desires to reduce the risk for CBC, obtain peace of mind, and improve survival were cited by most women as important reasons for having CPM. Although mutation carriers had a more accurate perception of their risk for CBC without CPM and about the efficacy of CPM as a risk-reducing 378 Strategy, noncarriers substantially overestimated their risk for CBC without CPM.
The 28.5% prevalence of CPM in our cohort exceeds the prevalence reported in the general population of patients with breast cancer and supports prior studies that have found that younger women are more likely to have CPM (1) (2) (3) (4) (5) 16) . A recent review of the literature found several studies that describe increasing rates of CPM (1, 2, 4, 5, 17); predictors of having CPM (3, (18) (19) (20) (21) (22) ; and selected outcomes related to CPM, such as satisfaction with and QOL after surgery (23) (24) (25) (26) (27) (28) (29) . Few studies, however, have specifically reported about the decision-making process and perceptions about how CPM might infiuence such outcomes as disease recurrence and survival.
Almost all women ranked a desire to improve survival or extend life and a desire to prevent metastatic disease as extremely or very important reasons for choosing CPM. However, most women understood that bilateral mastectomy would not lead to an extension of survival. This discordance suggests some degree of cognitive dissonance: Most women acknowledge that CPM does not improve survival, but anxiety and fear of recurrence probably influence women during the decision-making process, leading them to identify their desire to extend life and prevent metastatic disease as among the most important reasons for having CPM. Of note, women with a positive mutation were more likely to identify a survival benefit associated with bilateral mastectomy. Results from a recent study (30) suggest that prophylactic mastectomy alone might improve survival among women with BRCA mutations, but this has not been conclusively established as an effective mortalityreduction strategy in the absence of oophorectomy in highrisk women (31) .
Our results indicate that women who are not at increased genetic risk for contralaterai cancer overestimate the actual risk, with noncarriers estimating that a median of 10 women out of 100 would develop CBC without CPM within 5 years, which exceeds the actual risk of ap-proximately 2% to 4% over 5 years (1, 6, 7) . Other studies of women with ductal carcinoma in situ or invasive cancer have also documented overestimation of risk for CBC and recurrent disease (32) (33) (34) . Mutation carriers and noncarriers both overestimated their risk for recurrence in the chest wall area of the unaffected breast aftet CPM, which is estimated to be less than 1% (35, 36) over 5 years, thus underestimating the benefit of the procedure. Almost all mutation carriers were also more likely to perceive CPM as greatly reducing the risk for CBC compared with only 67% of noncarriers. In addition, only half of all women indicated that their physician had talked at least to some degree about reasons not to have CPM, suggesting that womeri, particularly those who do not have a genetic mutation, may not be informed by their health care providers that the risk for CBC is relatively low. Alternatively, some women may be told but are unable to comprehend their low risk, may simply not remember it accurately, or are unable to contextualize how this risk is relevant to them, possibly as a consequence of anxiety. Risk perceptions have been associated with anxiety in other breast cancer settings, including in at-risk women who have not developed the disease (32, 37, 38) .
In our study, physicians were identified as the most important sources of information; however, only one third of women cited a desire to follow a physician's recommendation as an extremely or a very important factor in their decision, and only 1 respondent listed physician recommendation as the single most important reason for having CPM. This finding is supported by recent studies in which patient-driven decision making has been identified as an important determinant of likelihood to have mastectomy (39, 40) .
Our findings suggest a potential role for interventions that ensure women are sufficiently informed and the actual risk for contralateral disease is effectively communicated, particularly in the context of other competing risks, such as metastatic recurrence. Some evidence suggests that decision aids can help to improve the quality of the decisionmaking process, specifically by reducing decisional conflict and enhancing knowledge (41) (42) (43) . In 1 randomized trial, breast-conserving surgery was the treatment more frequently chosen by women randomly assigned to the decision aid intervention (44) . Given the relationship between anxiety and overestimation of breast cancer risk, simply providing information might not be sufficient for wonien with high levels of distress (32, 45) . Better supportive care and management of anxiety surrounding diagnosis will probably enhance the effectiveness of any decision aid intervention.
The effect of CPM pn such outcomes as body image and sexuality should be an important consideration, given that young women are more likely than older women to have impaired QOL after a breast cancer diagnosis (46) (47) (48) (49) (50) . Many women in our sample reported that the eflFect CPM had on their appearance was worse than they exwww.annals.org pected, which is consistent with findings from several other studies where issues related to appearance and image persisted, in some cases, for many years after surgery (26, 27) . Although a substantial proportion of women (42%) reported that their sense, of sexuality after CPM was worse than expected, other studies have not found sexual problems to be prevalent. In a large retrospective study. Frost and colleagues (26) reported that only 23% of women related CPM to sexual relationship problems. A recent prospective analysis that measured sexual functioning in 60 women before and after CPM (27) detected no significant changes between the presurgical and postsurgical periods. Our study has limitations. Although several included items were from validated measures or were used in prior studies, the CPM survey itself is not a validated instrument. Respondents might also have misinterpreted certain survey items. The potential for recall bias must also be considered because the survey was completed an average of 2 years after surgery and some women might not accurately recall the details of how they approached their decision to have CPM.
Our study population was primarily white, nonHispanic, and college-educated; therefore, the generalizabiliry of our findings might be limited. Perceptions and knowledge about CPM and reasons for having the procedure might differ in a more diverse population. A relatively large number of women also reported a family history of breast cancer, a factor that might influence surgical choices. Furthermore, we only surveyed women who had CPM, and whether their responses difïer from those of women who did not have the procedure is unclear. This study sampled participants from an ongoing prospective cohort study; ongoing research includes exploring factors associated with other surgical choices and whether these differ between women who have CPM and those who do not.
Additional clarification of conflicting responsesspecifically, the inconsistencies between the importance of improved survival as a reason for choosing CPM and the acknowledgment that CPM is not associated with better survival outcomes-would be helpful. Future investigations might include focus groups or collection of qualitative data with the goal of elucidating the role of cognitive biases in making treatment decisions.
Although this is a cross-sectional, descriptive study, our findings provide important information about an understudied area and highlight the fact that many women have misperceptions about breast cancer risk. We believe that this points to a need for better risk communication strategies in an effort to ensure that treatment decision making is truly evidence-based while remaining patient-centered. Current author addresses and author contributions are available at www.annals.org.
